Baxter to acquire Immuno in $715 million deal
This article was originally published in Clinica
Baxter International is strengthening its biotech business with the acquisition of Swiss-based Immuno International. A staged purchase over three years will cost Baxter around $715 million in cash. Both companies' boards have sanctioned the deal, but approval of anti-trust authorities in Europe and the US is still required.